drugset / Trial / NCT01531803

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

NCT01531803

Phase 4 Terminated 3 enrolled Kedrion S.p.A. inVentiv Health Clinical · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

This is a randomized, controlled, open-label clinical trial aimed to evaluate the Safety of Kedbumin 25% Compared to Normal Saline Solution in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients Undergoing Major Elective Surgery. It will be conducted at approximately 5 surgical and pediatric intensive care units (SICU/NICU/PICU) in the US, over a period of 19 months, and the study population will consist of at least 60 male and female pediatric subjects between 0 days and 12 years of age, undergoing cardiac, abdominal, orthopedic or transplant surgery with an approximately equal number of subjects (n=10 to 25) in three of the four age groups: (29 days to 23 months), (2 to 5 years 11 months) and (6 years to 12 years) cohorts.

Timeline

Start
2015-02-05
Primary completion
2015-07-15
Completion
2015-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 0.5 g/kg Intravenous
Subject Albumin Protein / enzyme biologic 1 g/kg Intravenous

Indications

No indication recorded.